Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30877523 | 1.00 | CTSK (0.47) | CTSKF2F10PRSS1GAA | |
| SCHEMBL24263439 | 0.92 | F2 (0.53) | CTSKF2F10PRSS1GAA | |
| SCHEMBL16162636 | 0.90 | F2 (0.45) | CTSKF2F10PRSS1GAA | |
| SCHEMBL7219979 | 0.88 | F2 (0.45) | CTSKF2F10PRSS1GAA | |
| SCHEMBL10264999 | 0.85 | F2 (0.47) | CTSKF2F10PRSS1GAA | |
| SCHEMBL8081478 | 0.83 | F2 (0.51) | CTSKF2F10PRSS1GAA | |
| SCHEMBL4760690 | 0.83 | F2 (0.46) | CTSKF2F10PRSS1GAA | |
| SCHEMBL13259959 | 0.83 | F2 (0.51) | CTSKF2F10PRSS1GAA | |
| SCHEMBL7292123 | 0.83 | F2 (0.51) | CTSKF2F10PRSS1GAA | |
| SCHEMBL4760677 | 0.82 | F2 (0.55) | CTSKF2F10PRSS1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-01-31 | — | — | US | disclosed |
| US-6281227-B1 | INHIBITORS OF THE ACTIVITY OF FACTOR XA. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | STS, ARSA, F12 | CTSK 281/4885F2 11/4885F10 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.